Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2025 | LenCabo: lenvatinib and everolimus versus cabozantinib in metastatic ccRCC

Andrew Hahn • 17 Oct 2025
ESMO 2025
Genitourinary Cancer Kidney Cancer Cabozantinib Everolimus
LenCabo

Andrew Hahn, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the findings of the LenCabo trial (NCT05012371), a randomized Phase II multicenter trial of lenvatinib plus everolimus versus cabozantinib in patients with metastatic clear cell RCC (ccRCC) that progressed on PD-1 immune checkpoint inhibition. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Andrew Hahn

Emerging insights on TKI-associated muscle loss in renal cell carcinoma
1:14
Emerging insights on TKI-associated muscle loss in renal cell carcinoma
Andrew Hahn • 31 May 2026
Balancing efficacy and tolerability in second-line RCC treatment
1:17
Balancing efficacy and tolerability in second-line RCC treatment
Andrew Hahn • 31 May 2026
LenCabo: body composition and QoL with lenvatinib and everolimus in ccRCC
2:07
LenCabo: body composition and QoL with lenvatinib and everolimus in ccRCC
Andrew Hahn • 31 May 2026
New and upcoming treatments for clear cell renal cell carcinoma
1:31
New and upcoming treatments for clear cell renal cell carcinoma
Andrew Hahn • 17 Oct 2025

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026
The content of VJOncology is intended for healthcare professionals